ORCHPHARMA vs SANOFI: Stock Comparison

Orchid Pharma Limited vs Sanofi India Limited

Live data: 22 July 2026, 3:02 PM IST • Source: NSE and company filings

Sanofi India Limited is the larger company by market capitalisation. Orchid Pharma Limited shows faster revenue growth, while Sanofi India Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Orchid Pharma Limited and Sanofi India Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, ORCHPHARMA is more favourable on 2 of 13 scored metrics and SANOFI on 11These counts are context-free and are not an overall rating.

Key Differences

Market Cap
SANOFI is the larger company
₹7,850 Cr vs ₹5,072 Cr
P/E Ratio
SANOFI has a lower P/E
0x vs 253.09x
P/B Ratio
SANOFI has a lower P/B
0x vs 4.04x
EPS
SANOFI has higher earnings per share
₹134.59 vs ₹4.01
Dividend Yield
SANOFI has a higher dividend yield
7.15% vs 0%
Revenue Growth (TTM YoY)
ORCHPHARMA has faster revenue growth
-1.5% vs -11.9%
EPS Growth (TTM YoY)
ORCHPHARMA has faster EPS growth
0% vs -14.1%
Qtr Sales Growth
SANOFI has stronger quarterly sales growth
9.74% vs 0.05%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricORCHPHARMASANOFI
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricORCHPHARMASANOFI
Live Price₹1,000.7₹3,412.1
Day Change-2.18%0.85%
Volume82,38013,010
52-Week High₹1,119.8₹5,955
52-Week Low₹480₹3,054
Distance from 52W High-10.64%-42.7%

Valuation

MetricORCHPHARMASANOFI
Market Cap₹5,072 Cr₹7,850 Cr
P/E Ratio253.09x0x
P/B Ratio4.04x0x
EPS₹4.01₹134.59
Book Value₹253.98₹325.31
Dividend Yield0%7.15%

Growth

MetricORCHPHARMASANOFI
Revenue Growth (TTM YoY)-1.5%-11.9%
EPS Growth (TTM YoY)0%-14.1%
Qtr Sales Growth0.05%9.74%
Qtr Profit Growth4.26%22.4%

Profitability & Leverage

MetricORCHPHARMASANOFI
ROE2.12%47.1%
ROCE2.64%49.2%
Net Margin2.51%19.26%
Operating Margin5.07%24.4%
Debt to Equity0.28x0.02x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricORCHPHARMASANOFI
Promoter Holding69.84%0%
FII Holding0.87% 0.3 pp5.64% 0.09 pp
DII Holding20.25% 0.86 pp21.13% 0.18 pp
Public Holding9.05% 0.55 pp12.83% 0.09 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Orchid Pharma Limited and Sanofi India Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.